{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:34:33Z","timestamp":1785825273733,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1245\/s10434-024-16407-1","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:06:08Z","timestamp":1730739968000},"page":"209-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Using Open and Closed Abdomen Techniques for Colorectal Peritoneal Metastases and Peritoneal Pseudomyxoma Recurrences: Results from Six French Expert Centers"],"prefix":"10.1245","volume":"32","author":[{"given":"Fatah","family":"Tidadini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Arvieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sourrouille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Abba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Malgras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-C\u00e9cile","family":"Ezanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"issue":"1","key":"16407_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91. https:\/\/doi.org\/10.1038\/s41572-021-00326-6.","journal-title":"Nat Rev Dis Primers."},{"issue":"1","key":"16407_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/jcm12010103","volume":"12","author":"K Ren","year":"2022","unstructured":"Ren K, Xie X, Min T, et al. Development of the peritoneal metastasis: a review of back-grounds, mechanisms, treatments and prospects. J Clin Med. 2022;12(1):103. https:\/\/doi.org\/10.3390\/jcm12010103.","journal-title":"J Clin Med."},{"issue":"1","key":"16407_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3978\/j.issn.2078-6891.2015.112","volume":"7","author":"A Dehal","year":"2016","unstructured":"Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. J Gastrointest Oncol. 2016;7(1):143\u201357. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.112.","journal-title":"J Gastrointest Oncol."},{"issue":"2","key":"16407_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358\u201363. https:\/\/doi.org\/10.1002\/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o.","journal-title":"Cancer."},{"issue":"3","key":"16407_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363. https:\/\/doi.org\/10.1001\/jamasurg.2020.6363.","journal-title":"JAMA Surg."},{"issue":"1","key":"16407_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejso.2019.03.012","volume":"47","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Villeneuve L, Govaerts K, et al. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Eur J Surg Oncol. 2021;47(1):4\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.012.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"16407_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med."},{"issue":"1","key":"16407_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510098","volume":"99","author":"T Steffen","year":"2021","unstructured":"Steffen T, H\u00e4ller L, Bijelic L, et al. Decision-making analysis for hyperthermic intraperitoneal chemotherapy in ovarian cancer: a survey by the executive committee of the peritoneal surface oncology group international (PSOGI). Oncology. 2021;99(1):41\u20138. https:\/\/doi.org\/10.1159\/000510098.","journal-title":"Oncology."},{"issue":"11","key":"16407_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","volume":"19","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian V, Bhatt A, P\u00e9ron J, et al. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol. 2022;19(11):698\u2013718. https:\/\/doi.org\/10.1038\/s41571-022-00675-5.","journal-title":"Nat Rev Clin Oncol."},{"issue":"9","key":"16407_CR10","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370\u20137. https:\/\/doi.org\/10.1245\/s10434-010-1039-7.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"16407_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"3","key":"16407_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/02656736.2017.1337238","volume":"34","author":"TY Wang","year":"2018","unstructured":"Wang TY, Chen CY, Lu CH, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia. Int J Hyperthermia. 2018;34(3):328\u201335. https:\/\/doi.org\/10.1080\/02656736.2017.1337238.","journal-title":"Int J Hyperthermia."},{"issue":"13","key":"16407_CR13","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1245\/s10434-020-08482-x","volume":"27","author":"BD Powers","year":"2020","unstructured":"Powers BD, Felder S, Veerapong J, et al. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is not associated with prohibitive complications: results of a multiinstitutional retrospective study. Ann Surg Oncol. 2020;27(13):4883\u201391. https:\/\/doi.org\/10.1245\/s10434-020-08482-x.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 5","key":"16407_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1245\/s10434-016-5547-y","volume":"23","author":"RM Dodson","year":"2016","unstructured":"Dodson RM, McQuellon RP, Mogal HD, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(Suppl 5):772\u201383. https:\/\/doi.org\/10.1245\/s10434-016-5547-y.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"16407_CR15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1245\/s10434-017-6326-0","volume":"25","author":"AT Stearns","year":"2018","unstructured":"Stearns AT, Malcomson L, Punnett G, et al. Long-term quality of life after cytoreductive surgery and heated intraperitoneal chemotherapy for pseudomyxoma peritonei: a prospective longitudinal study. Ann Surg Oncol. 2018;25(4):965\u201373. https:\/\/doi.org\/10.1245\/s10434-017-6326-0.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"16407_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11605-019-04463-y","volume":"24","author":"TC Lee","year":"2020","unstructured":"Lee TC, Wima K, Sussman JJ, et al. Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a US HIPEC collaborative study. J Gastrointest Surg. 2020;24(1):165\u201376. https:\/\/doi.org\/10.1007\/s11605-019-04463-y.","journal-title":"J Gastrointest Surg."},{"issue":"1","key":"16407_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1245\/s10434-017-6108-8","volume":"25","author":"KJ Kelly","year":"2018","unstructured":"Kelly KJ, Cajas L, Baumgartner JM, Lowy AM. Factors associated with 60-day readmission following cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(1):91\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"20","key":"16407_CR18","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449\u201356. https:\/\/doi.org\/10.1200\/JCO.2011.39.7166.","journal-title":"J Clin Oncol."},{"issue":"10","key":"16407_CR19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ejso.2015.05.018","volume":"41","author":"TR van Oudheusden","year":"2015","unstructured":"van Oudheusden TR, Nienhuijs SW, Luyer MD, et al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review. Eur J Surg Oncol. 2015;41(10):1269\u201377. https:\/\/doi.org\/10.1016\/j.ejso.2015.05.018.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"16407_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/ASO.2004.08.014","volume":"11","author":"VJ Verwaal","year":"2004","unstructured":"Verwaal VJ, Boot H, Aleman BMP, van Tinteren H, Zoetmulder FAN. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11(4):375\u20139. https:\/\/doi.org\/10.1245\/ASO.2004.08.014.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"16407_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3978\/j.issn.2078-6891.2015.131","volume":"7","author":"H Mogal","year":"2016","unstructured":"Mogal H, Chouliaras K, Levine EA, Shen P, Votanopoulos KI. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol. 2016;7(1):129\u201342. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.131.","journal-title":"J Gastrointest Oncol."},{"key":"16407_CR22","unstructured":"Chimiohyperthermie intrap\u00e9riton\u00e9ale (CHIP) associ\u00e9e ou non \u00e0 une chirurgie de cytoreduction pr\u00e9alable. 2021. Available at: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/rapport_chip.pdf. Accessed 8 Feb 2023."},{"issue":"4","key":"16407_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jso.21061","volume":"98","author":"O Glehen","year":"2008","unstructured":"Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98(4):242\u20136. https:\/\/doi.org\/10.1002\/jso.21061.","journal-title":"J Surg Oncol."},{"issue":"7","key":"16407_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4251\/wjgo.v12.i7.756","volume":"12","author":"JL Leiting","year":"2020","unstructured":"Leiting JL, Cloyd JM, Ahmed A, et al. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol. 2020;12(7):756\u201367. https:\/\/doi.org\/10.4251\/wjgo.v12.i7.756.","journal-title":"World J Gastrointest Oncol."},{"issue":"13","key":"16407_CR25","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, de Hingh I, Van Der Speeten K, et al. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28(13):9098\u2013113. https:\/\/doi.org\/10.1245\/s10434-021-10193-w.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"16407_CR26","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10434-999-0790-0","volume":"6","author":"AD Stephens","year":"1999","unstructured":"Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790\u20136. https:\/\/doi.org\/10.1007\/s10434-999-0790-0.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"16407_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","volume":"208","author":"S Fujimoto","year":"1988","unstructured":"Fujimoto S, Shrestha RD, Kokubun M, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988;208(1):36\u201341. https:\/\/doi.org\/10.1097\/00000658-198807000-00005.","journal-title":"Ann Surg."},{"issue":"9","key":"16407_CR28","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1245\/s10434-011-1651-1","volume":"18","author":"E Cotte","year":"2011","unstructured":"Cotte E, Passot G, Tod M, et al. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol. 2011;18(9):2599\u2013603. https:\/\/doi.org\/10.1245\/s10434-011-1651-1.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"16407_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"issue":"3","key":"16407_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1214\/aoms\/1177729380","volume":"23","author":"WG Cochran","year":"1952","unstructured":"Cochran WG. The \u03c72 test of goodness of fit. Ann Math Stat. 1952;23(3):315\u201345. https:\/\/doi.org\/10.1214\/aoms\/1177729380.","journal-title":"Ann Math Stat."},{"issue":"9","key":"16407_CR31","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1245\/s10434-021-09684-7","volume":"28","author":"S Laks","year":"2021","unstructured":"Laks S, Schtrechman G, Adileh M, et al. Repeat cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer peritoneal recurrences is safe and efficacious. Ann Surg Oncol. 2021;28(9):5330\u20138. https:\/\/doi.org\/10.1245\/s10434-021-09684-7.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"16407_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ejso.2015.07.004","volume":"41","author":"Y Huang","year":"2015","unstructured":"Huang Y, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2015;41(10):1373\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2015.07.004.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"16407_CR33","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1245\/s10434-013-3341-7","volume":"21","author":"J Wong","year":"2014","unstructured":"Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014;21(5):1480\u20136. https:\/\/doi.org\/10.1245\/s10434-013-3341-7.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"16407_CR34","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ejso.2016.03.017","volume":"42","author":"N Ansari","year":"2016","unstructured":"Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42(7):1035\u201341. https:\/\/doi.org\/10.1016\/j.ejso.2016.03.017.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"16407_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1245\/ASO.2004.07.002","volume":"11","author":"M Deraco","year":"2004","unstructured":"Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11(4):393\u20138. https:\/\/doi.org\/10.1245\/ASO.2004.07.002.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"16407_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12957-024-03386-6","volume":"22","author":"M Sarofim","year":"2024","unstructured":"Sarofim M, Wijayawardana R, Ahmadi N, Morris DL. Repeat cytoreductive surgery with HIPEC for colorectal peritoneal metastases: a systematic review. World J Surg Oncol. 2024;22(1):99. https:\/\/doi.org\/10.1186\/s12957-024-03386-6.","journal-title":"World J Surg Oncol."},{"issue":"3","key":"16407_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ejso.2014.08.476","volume":"41","author":"AC Lord","year":"2015","unstructured":"Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol. 2015;41(3):396\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2014.08.476.","journal-title":"Eur J Surg Oncol."},{"issue":"6","key":"16407_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12664-017-0799-4","volume":"36","author":"AZ Azzam","year":"2017","unstructured":"Azzam AZ, Alyahya ZA, Wusaibie AAA, Amin TM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: a single-center experience. Indian J Gastroenterol. 2017;36(6):452\u20138. https:\/\/doi.org\/10.1007\/s12664-017-0799-4.","journal-title":"Indian J Gastroenterol."},{"issue":"3","key":"16407_CR39","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1245\/s10434-023-14608-8","volume":"31","author":"E Sarfaty","year":"2024","unstructured":"Sarfaty E, Khajoueinejad N, Yu AT, et al. Actual 5-year survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2024;31(3):1970\u20139. https:\/\/doi.org\/10.1245\/s10434-023-14608-8.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"16407_CR40","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jamcollsurg.2006.08.024","volume":"203","author":"RG da Silva","year":"2006","unstructured":"da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878\u201386. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2006.08.024.","journal-title":"J Am Coll Surg."},{"issue":"1","key":"16407_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/1097-0142(20010701)92:1<71::aid-cncr1293>3.0.co;2-9","volume":"92","author":"D Elias","year":"2001","unstructured":"Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92(1):71\u20136. https:\/\/doi.org\/10.1002\/1097-0142(20010701)92:1%3c71::aid-cncr1293%3e3.0.co;2-9.","journal-title":"Cancer."},{"issue":"3","key":"16407_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/02656736.2016.1262064","volume":"33","author":"G Tan","year":"2017","unstructured":"Tan G, Chia C, Kumar M, et al. 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. Int J Hyperthermia. 2017;33(3):288\u201394. https:\/\/doi.org\/10.1080\/02656736.2016.1262064.","journal-title":"Int J Hyperthermia."},{"key":"16407_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2023.102012","volume":"51","author":"Y Kamada","year":"2023","unstructured":"Kamada Y, Hida K, Yonemura Y, et al. Analysis of the characteristics and outcomes of patients with pseudomyxoma peritonei of appendiceal origin treated with curative-intent surgery. Surg Oncol. 2023;51:102012. https:\/\/doi.org\/10.1016\/j.suronc.2023.102012.","journal-title":"Surg Oncol."},{"issue":"5","key":"16407_CR44","first-page":"2504","volume":"25","author":"J Spiliotis","year":"2020","unstructured":"Spiliotis J, Prodromidou A, Ferfelis M, et al. Is there a role of repeat cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with relapse from peritoneal metastatic disease? A survival analysis. J BUON. 2020;25(5):2504\u20139.","journal-title":"J BUON."},{"key":"16407_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-016-0804-x","author":"N Vassos","year":"2016","unstructured":"Vassos N, F\u00f6rtsch T, Aladashvili A, Hohenberger W, Croner RS. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. World J Surg Oncol. 2016. https:\/\/doi.org\/10.1186\/s12957-016-0804-x.","journal-title":"World J Surg Oncol."},{"issue":"2","key":"16407_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jso.23062","volume":"106","author":"N Golse","year":"2012","unstructured":"Golse N, Bakrin N, Passot G, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012;106(2):197\u2013203. https:\/\/doi.org\/10.1002\/jso.23062.","journal-title":"J Surg Oncol."},{"issue":"3","key":"16407_CR47","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2012.04.023","volume":"215","author":"KI Votanopoulos","year":"2012","unstructured":"Votanopoulos KI, Ihemelandu C, Shen P, Stewart JH, Russell GB, Levine EA. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215(3):412\u20137. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2012.04.023.","journal-title":"J Am Coll Surg."},{"issue":"11","key":"16407_CR48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ejso.2013.08.017","volume":"39","author":"A Sardi","year":"2013","unstructured":"Sardi A, Jimenez WA, Nieroda C, Sittig M, Macdonald R, Gushchin V. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Eur J Surg Oncol. 2013;39(11):1207\u201313. https:\/\/doi.org\/10.1016\/j.ejso.2013.08.017.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"16407_CR49","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","volume":"22","author":"C Ihemelandu","year":"2015","unstructured":"Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22(5):1680\u20135.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"16407_CR50","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1245\/s10434-019-07218-w","volume":"26","author":"HA Choudry","year":"2019","unstructured":"Choudry HA, Bednar F, Shuai Y, et al. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases. Ann Surg Oncol. 2019;26(5):1445\u201353. https:\/\/doi.org\/10.1245\/s10434-019-07218-w.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16407-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:08:14Z","timestamp":1734631694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16407-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["16407"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16407-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Olivier Glehen is a consultant for Gamida. Fatah Tidadini, Catherine Arvieux, Isabelle Sourrouille, Fr\u00e9d\u00e9ric Marchal, Julio Abba, Brice Malgras, Jean-Louis Quesada, Marc Pocard, and Anne-C\u00e9cile Ezanno have no conflicts of interest to declare that may be relevant to the contents of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in this study were in accordance with the Ethical Standards Research Committee and the Helsinki Declaration. The study was registered in the internal register of the Grenoble Alpes University Hospital of studies respecting the reference methodology MR004 of the French National Commission for Informatics and Freedoms (CNIL).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients were informed that their anonymized data might be the subject of clinical research in the future and that they could oppose this by informing the doctor.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The contents of this study are solely the responsibility of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Data are available for bona fide researchers upon written request to the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}